Format

Send to

Choose Destination
Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:26-30. doi: 10.1016/S0213-005X(15)30006-9.

[Efficacy of dolutegravir in treatment-experienced patients: the SAILING and VIKING trials].

[Article in Spanish]

Author information

1
Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, Madrid, España; Instituto de Investigación Sanitaria Ramón y Cajal (IRYCIS), Madrid, España.
2
Unidad de Enfermedades Infecciosas-VIH, Hospital General Universitario Gregorio Marañón, Madrid, España; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, España. Electronic address: jbb4@me.com.

Abstract

Dolutegravir is an HIV integrase inhibitor with a high genetic barrier to resistance and is active against raltegravir- and/or elvitegravir-resistant strains. The clinical development of dolutegravir for HIV infection rescue therapy is based on 3 clinical trials. In the SAILING trial, dolutegravir (5 mg once daily) in combination with 2 other antiretroviral agents was well tolerated and showed greater virological effect than raltegravir (400 mg twice daily) in the treatment of integrase inhibitor-naïve adults with virological failure infected with HIV strains with at least two-class drug resistance. The VIKING studies were designed to evaluate the efficacy of dolutegravir as rescue therapy in treatment-experienced patients infected with HIV strains with resistance mutations to raltegravir and/or elvitegravir. VIKING-1-2 was a dose-ranging phase IIb trial. VIKING-3 was a phase III trial in which dolutegravir (50 mg twice daily) formed part of an optimized regimen and proved safe and effective in this difficult-to-treat group of patients. Dolutegravir is the integrase inhibitor of choice for rescue therapy in multiresistant HIV infection, both in integrase inhibitor-naïve patients and in those previously treated with raltegravir or elvitegravir.

KEYWORDS:

Antiretroviral therapy; Dolutegravir; Drug resistance; HIV; HIV integrase inhibitors; Inhibidores de la integrasa de VIH; Resistencia a fármacos; Tratamiento antirretroviral; VIH

PMID:
25858609
DOI:
10.1016/S0213-005X(15)30006-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center